CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The HIPGEN project is focused on developing a novel cell therapy to enhance recovery after hip fracture surgery. By using placental-derived cells, it aims to improve muscle regeneration and reduce stress in elderly patients, ultimately addressing significant health challenges associated with hip fractures.
Aim of the HIPGEN project is to develop the first cell therapy to improve functional recovery following hip fracture arthroplasty.
Hip fractures are a major public health concern in the EU with an increasing incidence of 1 million patients per year, high direct and indirect costs and high mortality.
Conventional therapies are not able to address the main medical problems of hip fracture in these elderly patients, being the impairment of mobility and the stress imposed as a combined result of inj…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Oxford
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Denmark, Vejle
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Italy, Brescia
Type: Research institute
Activity type: Research Organisations
SME: No
Israel, Haifa
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
